

Disclaimer

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.



First-quarter highlights

Marco Gadola, CEO

Good start to 2019 – further growth initiatives taken

REVENUE

GROWTH

TOP PERFORMERS

CHF 372m

Up 15% on strong 2018 performance

+17% organic¹

2.3%-point FX effect Minor acquisition effect

APAC & LATAM

...sustain growth around 20%; NAM & EMEA both post doubledigit increases

INNOVATION STREAM

PORTFOLIO

OUTLOOK²

>100 new articles

...introduced at key trade events; clear aligner business launched in LATAM, Europe & China Business expansion


Stakes increased in Anthogyr, Zinedent, Medentika and Valoc; distribution agreement with Medit Outperformance

2019: organic revenue to grow in low-teen percentage range; further improvements in EBITDA and EBIT margins



¹ Organic growth – i.e. excluding the effects of currency fluctuations and acquired/divested business activities. ² Outlook expectations barring unforeseen events/circumstances and assuming fairly stable FOREX.

Strong growth continues – on track to deliver our full-year promises




Business and regional review


Peter Hackel, CFO

EMEA and NAM contribute two-thirds of organic growth

Revenue development (in CHF m, rounded)



Regional share of organic growth



EMEA & North America outpacing the market


EMEA




North America



Revenue change (organic)







- EMEA performance fuelled by countries in Eastern Europe and the Middle East
- Key performers: Russia, Austria, and Turkey; strong growth in Germany
- Good growth across the board, except for digital hardware (typical pattern pre-IDS)
- Robust demand for premium implant and abutment solutions
- Value implants growing faster than premium
- Biomaterials benefit from Jason membrane launch and cross-selling
- Dynamic growth in clear-aligner cases continues

Strong performance in Asia Pacific & Latin America








- China maintains dynamism
- Japan progresses well
- Neodent rolled out in Australia, Indonesia and Thailand









- Argentina, Chile, Colombia and Mexico all continue to deliver strong growth
- Solid single-digit growth in the largest market, Brazil
- ClearCorrect launched at CIOSP in February

Dynamic clear-aligner and biomaterials business

Implants



Restorative & Digital



Biomaterials



Recent achievements & strategy in action

Marco Gadola, CEO

Anthogyr – a high-quality European brand to further penetrate the attractive non-premium segment



- Stake increased from 30% to full ownership
- Consolidation 1 June 2019; integration started
- Leading French implant manufacturer; established international provider of upper value implants
- Comprehensive implant portfolio
- Group to build on successful partnership in China and Russia
- Anthogyr employs 400 people
- Total revenues last 12 months: CHF 57 million (approx. CHF 50 million acquisition effect¹)



Further jewels in the crown

MEDENTIKA®


- Stake increased from 51% to 91%
- Attractively-priced compatible prosthetics and implants



- Participation increased from 50% to full ownership
- Implants to address the lower value segment in Turkey,
 Middle East, N. Africa, and Eurasia
- Consolidated as of 1 January 2019

VALOC

- Stake increased from 44% to a controlling 55%
- High-performance retention devices for implant-borne removable dentures



straumanngroup Esthetic dentistry solutions portfolio

	Implant systems	Multi-platform prosthetics	Digital	Orthodontic	Biomaterials	Preventive
Global brands	straumann nthagyr medentika neodent	O MEDENTIKA®	straumann dental wings	clearcerrect	straumann	straumann
Local brands	zinedent equínox T-PLUS Dental Implant			s w yle tec		
Technology brands & partners	Z-SYSTEMS ceramic implants	RODO VALOC	coDiagnostiX DENTAL MONITORING rapidshape MEDIT 3 shape AMANNGIRRBACH Zirkon zahn	GENIOVA THE FAST ALIGNER	bone & tissue regeneration GENOSS For Patients & Doctors Conclude Health Saving Lives. Restoring Health. Giving Hope.	credentis (ACTEON dentognostics EMS** RUBICON LIFE SCIENCE BrightTonix

Innovation showcased at key events



- Huge presence at AO, Chicago Midwinter, CIOSP & IDS
- Key innovations launched; >100 new items presented
- >50 lectures/live sessions at booths
- Tens of thousands of views online
- >3000 customer leads

Watch the IDS video
https://www.youtube.com/watch?
v=GULQa2ozUjU

Meeting requirements for immediate solutions e.g. in edentulous treatments











Removable solutions



Straumann Mini-Implantat



Straumann Novaloc

Fixed solutions



Straumann BLT and angulated abutments



Straumann BLX



Straumann Pro Arch

An even broader range of digital options










Medit T-Series





DWOS 8 & CoDiagnostiX with Easy Modes; Carestream, Camfacture, Medit integrated















Archiving

& Bridge

Prosthetics

Partial Frameworks Dentures

Full

Model Builder

Bite Splints

Clear-aligner business launched in Brazil, China and Europe

ClearCorrect

- Launched in Brazil and Europe
- Production expansion
- Fresh new branding

Smyletec

- Exclusive distribution agreement
- Affordable, state-of-the-art solutions for China
- World's second largest market for clear aligners, expected to grow >50% p.a. in the next 5 years
- Smyletec launched in March; Dental Monitoring to follow later in 2019



Group expands production in Brazil





- Construction of new plant in Curitiba underway
- 11 000m² production space created in first phase
- Automated production of ClearCorrect clear aligners to serve LATAM market
- Increased capacity for implant system components
- Scheduled opening in Q4 2019

ClearCorrect and Align Technology settle patent disputes

- Companies agree to drop patent disputes
- Non-binding letter of intent to explore distribution & development of Align's iTero® IO-scanner integrated in Straumann's CARES® / DWOS® workflow
- Straumann Group expects one-time expense of max CHF 24m in H1 2019, including CHF 16m, if distribution & development agreement does not materialize

Inspiring and engaging women in implant dentistry



- First WIN EMEA summit attended by 160 female dental professionals from 27 nations
- #Power-up: Women@Straumann internal program for female colleagues reflects external initiative
- JUNTAS empowering women in Brazil; >200 female colleagues join program



straumanngroup

Outlook 2019

Our 2019 guidance Barring unforeseen circumstances

Market growth

Global implant market to continue to grow between 4-5%

Our revenue growth

Confident to outperform and achieve organic revenue growth in the low-teens percentage range

Profitability

Further improvement in the underlying¹ EBITDA and EBIT margin



¹ Profitability objectives exclude exceptional effects related to acquisitions, business combinations as well as the impact from the adoption of IFRS16 (see next slide).

Estimated impact from adopting IFRS 16 (leases) in 2019

Approx. IFRS 16 impact (in CHF million) ¹	Total
Revenue	
Gross margin	+0.5
EBITDA	+18.0
EBIT	+3.0
Financial results	-5.0
Profit before tax	-2.0

¹ Barring unforeseen circumstances, major currency movements and/or change in business scope


Questions & answers



Calendar of upcoming events

2019	Event	Location	
30 April	First-quarter results	Webcast	
21 May	UBS Healthcare conference	New York	
22 May	Berenberg US conference	Tarrytown (US)	
04-05 June	Vontobel Switzerland conference	Interlaken (CH)	
13 June	Exane BNP Paribas CEO conference	Paris	
14 August	First-half 2019 results conference	Basel, HQ	
Social media	Туре	Source	
Analyst Talk	Executive interviewed by analysts	Corporate Website / youtube	
StraumannIR	Investor Relations Twitter		


Straumann's currency exposure



EUR

22%

Average exchange rates (rounded)					FX sensitivity (+/- 10%) on full-year	
		2017	2018	Closing 2018	Revenue	EBIT
1	EURCHF	1.11	1.15	1.13	+/- 39m	+/- 23m
1	USDCHF	0.98	0.98	0.99	+/- 37m	+/- 17m
100	BRLCHF	30.69	26.87	25.36	+/- 11m	+/- 2m
100	JPYCHF	0.87	0.88	0.90	+/- 7m	+/- 4m



¹ These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2018 figures as well as average FX rates in 2017-18. They also include recent acquisitions and new subsidiaries.



USD/CAD/AUD 26%

